{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T19:52:44Z","timestamp":1785441164916,"version":"3.56.0"},"reference-count":89,"publisher":"BMJ","issue":"12","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the National Key Research and Development Program of China"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2018,9,27]]},"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of anti-vascular endothelial growth factor (VEGF) agents and corticosteroids for the treatment of macular oedema (ME) secondary to central retinal vein occlusion (CRVO).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Systematic review and network meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Patients from previously reported randomised controlled trials (RCTs) comparing anti-VEGF and corticosteroids for the treatment of ME secondary to CRVO.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Literature searches were conducted using PubMed, Medline, Embase, Cochrane Library and clinicaltrials.gov until March 2017. Therapeutic effects were estimated using the proportions of patients gaining\/losing \u226515 letters, best-corrected visual acuity (BCVA) and central retinal thickness (CRT). Treatment safety was estimated using the proportions of adverse events, namely increased intraocular pressure (IOP), cataracts, vitreous haemorrhage (VH) and retinal tear. The software ADDIS (V.1.16.8) was used for analysis. Treatment effect and safety of different drugs could be ranked based on simulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eleven RCTs comprising 2060 patients were identified. Regarding patients gaining \u226515 letters, aflibercept and ranibizumab were significantly more effective than sham\/placebo at 6 months. Regarding patients losing \u226515 letters at 6 months, ranibizumab showed significant improvement compared with dexamethasone. Aflibercept, bevacizumab or ranibizumab showed greater improvements in BCVA than sham\/placebo at 6 months. Intravitreal ranibizumab injection demonstrated greater CRT reduction than both sham and dexamethasone did. Dexamethasone had a higher risk of increased IOP than aflibercept and ranibizumab. Ranibizumab demonstrated a greater risk of cataracts than dexamethasone. Aflibercept and ranibizumab demonstrated low incidence of VH and retinal tear, respectively. Aflibercept had a slight advantage over ranibizumab as assessed by benefit\u2013risk analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Anti-VEGF agents have advantages in the treatment of ME secondary to CRVO. Aflibercept and ranibizumab showed marked BCVA improvement and CRT reduction. Aflibercept may have a slight advantage over ranibizumab. The results of this study can serve as a reference for clinicians to provide patient-tailored treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42017064076.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2018-022700","type":"journal-article","created":{"date-parts":[[2018,12,28]],"date-time":"2018-12-28T13:35:13Z","timestamp":1546004113000},"page":"e022700","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":18,"title":["Comparison of the efficacy and safety of drug therapies for macular edema secondary to central retinal vein occlusion"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7359-911X","authenticated-orcid":false,"given":"Tianwei","family":"Qian","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine; Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengya","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine; Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjing","family":"Wan","sequence":"additional","affiliation":[{"name":"School of Information Science and Engineering, East China University of Science and Technology, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MengXiao","family":"Li","sequence":"additional","affiliation":[{"name":"School of Information Science and Engineering, East China University of Science and Technology, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine; Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,12,28]]},"reference":[{"key":"2025121403524152000_8.12.e022700.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.07.017"},{"key":"2025121403524152000_8.12.e022700.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2008.08.016"},{"key":"2025121403524152000_8.12.e022700.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.01.060"},{"key":"2025121403524152000_8.12.e022700.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.04.019"},{"key":"2025121403524152000_8.12.e022700.5","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1996.01100130537006"},{"key":"2025121403524152000_8.12.e022700.6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-9071.2011.02713.x"},{"key":"2025121403524152000_8.12.e022700.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)70001-7"},{"key":"2025121403524152000_8.12.e022700.8","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.124.5.726"},{"key":"2025121403524152000_8.12.e022700.9","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.126.4.513"},{"key":"2025121403524152000_8.12.e022700.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(95)30849-4"},{"key":"2025121403524152000_8.12.e022700.11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/00055735-199806000-00008","article-title":"Current concepts in the management of central retinal vein occlusion","volume":"9","author":"Cooney","year":"1998","journal-title":"Curr Opin Ophthalmol"},{"key":"2025121403524152000_8.12.e022700.12","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2011.92"},{"key":"2025121403524152000_8.12.e022700.13","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.122.8.1131"},{"key":"2025121403524152000_8.12.e022700.14","doi-asserted-by":"publisher","DOI":"10.1097\/00006982-200510000-00005"},{"key":"2025121403524152000_8.12.e022700.15","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-006-0348-9"},{"key":"2025121403524152000_8.12.e022700.16","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.125.3.309"},{"key":"2025121403524152000_8.12.e022700.17","doi-asserted-by":"publisher","DOI":"10.1210\/er.18.1.4"},{"key":"2025121403524152000_8.12.e022700.18","doi-asserted-by":"publisher","DOI":"10.1023\/A:1002136712070"},{"key":"2025121403524152000_8.12.e022700.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199412013312203"},{"key":"2025121403524152000_8.12.e022700.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.12.005"},{"key":"2025121403524152000_8.12.e022700.21","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1089\/jop.2011.0050","article-title":"Intravitreal bevacizumab for treatment of macular edema secondary to central retinal vein occlusion: eighteen-month results of a prospective trial","volume":"27","author":"Zhang","year":"2011","journal-title":"J Ocul Pharmacol Ther"},{"key":"2025121403524152000_8.12.e022700.22","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10384-016-0476-7","article-title":"Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion","volume":"61","author":"Saishin","year":"2017","journal-title":"Jpn J Ophthalmol"},{"key":"2025121403524152000_8.12.e022700.23","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2009.14"},{"key":"2025121403524152000_8.12.e022700.24","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-005292","article-title":"Drug treatment of macular oedema secondary to central retinal vein occlusion: a network meta-analysis","volume":"4","author":"Ford","year":"2014","journal-title":"BMJ Open"},{"key":"2025121403524152000_8.12.e022700.25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097"},{"key":"2025121403524152000_8.12.e022700.26","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385"},{"key":"2025121403524152000_8.12.e022700.27","unstructured":"Higgins JPT , Altman DG , Sterne JAC . Chapter 8: Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0: The Cochrane Collaboration, 2011."},{"key":"2025121403524152000_8.12.e022700.28","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-159-2-201307160-00008"},{"key":"2025121403524152000_8.12.e022700.29","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-014-2994-2"},{"key":"2025121403524152000_8.12.e022700.30","doi-asserted-by":"publisher","DOI":"10.1177\/0962280207080643"},{"key":"2025121403524152000_8.12.e022700.31","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1875"},{"key":"2025121403524152000_8.12.e022700.32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.331.7521.897"},{"key":"2025121403524152000_8.12.e022700.33","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.recesp.2013.11.016","article-title":"The Transitive Property Across Randomized Controlled Trials: If B Is Better Than A, and C Is Better Than B, Will C Be Better Than A?","volume":"67","author":"Catal\u00e1-L\u00f3pez","year":"2014","journal-title":"Revista Espa\u00f1ola de Cardiolog\u00eda"},{"key":"2025121403524152000_8.12.e022700.34","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3767"},{"key":"2025121403524152000_8.12.e022700.35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLoS One"},{"key":"2025121403524152000_8.12.e022700.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.dss.2012.10.005"},{"key":"2025121403524152000_8.12.e022700.37","doi-asserted-by":"publisher","DOI":"10.1214\/ss\/1177011136"},{"key":"2025121403524152000_8.12.e022700.38","doi-asserted-by":"publisher","DOI":"10.1080\/10618600.1998.10474787"},{"key":"2025121403524152000_8.12.e022700.39","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.ophtha.2016.01.011","article-title":"Individualized Ranibizumab Regimen Driven by Stabilization Criteria for Central Retinal Vein Occlusion: Twelve-Month Results of the CRYSTAL Study","volume":"123","author":"Larsen","year":"2016","journal-title":"Ophthalmology"},{"key":"2025121403524152000_8.12.e022700.40","article-title":"Intravitreal injection of bevacizumab alone or with triamcinolone acetonide for treatment of macular edema caused by central retinal vein occlusion","volume":"4","author":"Wang","year":"2011","journal-title":"Int J Ophthalmol"},{"key":"2025121403524152000_8.12.e022700.41","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000369566","article-title":"Intravitreal ranibizumab versus isovolemic hemodilution in the treatment of macular edema secondary to central retinal vein occlusion: twelve-month results of a prospective, randomized, multicenter trial","volume":"233","author":"Kreutzer","year":"2015","journal-title":"Ophthalmologica"},{"key":"2025121403524152000_8.12.e022700.42","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181f4420d"},{"key":"2025121403524152000_8.12.e022700.43","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/ceo.12311","article-title":"Dexamethasone intravitreous implant versus bevacizumab for central retinal vein occlusion-related macular oedema: a prospective randomized comparison","volume":"42","author":"Gado","year":"2014","journal-title":"Clin Exp Ophthalmol"},{"key":"2025121403524152000_8.12.e022700.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.03.032"},{"key":"2025121403524152000_8.12.e022700.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.05.014"},{"key":"2025121403524152000_8.12.e022700.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.12.028"},{"key":"2025121403524152000_8.12.e022700.47","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00417-012-2134-1","article-title":"A prospective, randomised, multicenter trial for surgical treatment of central retinal vein occlusion: results of the Radial Optic Neurotomy for Central Vein Occlusion (ROVO) study group","volume":"251","author":"Aggermann","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2025121403524152000_8.12.e022700.48","first-page":"5194","article-title":"Reading center evaluation of OCT images from patients enrolled in the standard care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) Study","volume":"47","author":"Myers","year":"2006","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"2025121403524152000_8.12.e022700.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2007.04.011"},{"key":"2025121403524152000_8.12.e022700.50","first-page":"107","article-title":"Temporal variability of OCT in retinal vein occlusion participants in the SCORE study","volume":"48","author":"Oden","year":"2007","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"2025121403524152000_8.12.e022700.51","unstructured":"Ip M , Oden N , VanVeldhuisen P , et al . The standard care vs. corticosteroid for retinal vein occlusion study: design and baseline characteristics. Am Acad Ophthalmol 2008:260."},{"key":"2025121403524152000_8.12.e022700.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2008.10.017"},{"key":"2025121403524152000_8.12.e022700.53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2008.11.015"},{"key":"2025121403524152000_8.12.e022700.54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.03.022"},{"key":"2025121403524152000_8.12.e022700.55","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2009.277"},{"key":"2025121403524152000_8.12.e022700.56","doi-asserted-by":"crossref","DOI":"10.1001\/archophthalmol.2009.234","article-title":"A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5","volume":"127","author":"Ip","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"2025121403524152000_8.12.e022700.57","doi-asserted-by":"crossref","DOI":"10.1001\/archophthalmol.2009.233","article-title":"A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6","volume":"127","author":"Scott","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"2025121403524152000_8.12.e022700.58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2009.06.004"},{"key":"2025121403524152000_8.12.e022700.59","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2010.193"},{"key":"2025121403524152000_8.12.e022700.60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.06.034"},{"key":"2025121403524152000_8.12.e022700.61","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.ophtha.2010.11.020","article-title":"SCORE Study report #11: incidences of neovascular events in eyes with retinal vein occlusion","volume":"118","author":"Chan","year":"2011","journal-title":"Ophthalmology"},{"key":"2025121403524152000_8.12.e022700.62","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/IAE.0b013e318263d106","article-title":"Score Study Report 12: Development of venous collaterals in the Score Study","volume":"33","author":"Weinberg","year":"2013","journal-title":"Retina"},{"key":"2025121403524152000_8.12.e022700.63","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/eye.2012.59","article-title":"Association of outer retinal layer morphology with visual acuity in patients with retinal vein occlusion: SCORE Study Report 13","volume":"26","author":"Domalpally","year":"2012","journal-title":"Eye"},{"key":"2025121403524152000_8.12.e022700.64","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1001\/archophthalmol.2012.2728","article-title":"Baseline characteristics and response to treatment of participants with hemiretinal compared with branch retinal or central retinal vein occlusion in the standard care vs corticosteroid for retinal vein occlusion (SCORE) study: SCORE study report 14","volume":"130","author":"Scott","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"2025121403524152000_8.12.e022700.65","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.02.022"},{"key":"2025121403524152000_8.12.e022700.66","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.02.038"},{"key":"2025121403524152000_8.12.e022700.67","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2010.03.028"},{"key":"2025121403524152000_8.12.e022700.68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.01.042"},{"key":"2025121403524152000_8.12.e022700.69","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2012.09.026"},{"key":"2025121403524152000_8.12.e022700.70","first-page":"44","article-title":"Intravitreal Vegf Trap-eye In Central Retinal Vein Occlusion: Results Of The Phase 3 Copernicus And Galileo Studies","volume":"40","author":"Gillies","year":"2012","journal-title":"Clinical & Experimental Ophthalmology"},{"key":"2025121403524152000_8.12.e022700.71","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2012-301504"},{"key":"2025121403524152000_8.12.e022700.72","article-title":"Long-term benefit from bevacizumab for macular edema in central retinal vein occlusion: 12-month results of a prospective study","volume":"90","author":"Epstein","year":"2012","journal-title":"Acta Ophthalmologica"},{"key":"2025121403524152000_8.12.e022700.73","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.01.022"},{"key":"2025121403524152000_8.12.e022700.74","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.06.037"},{"key":"2025121403524152000_8.12.e022700.75","first-page":"4279","article-title":"Pegabtanib sodium for treatment of macular edema secondary to Central Retinal Vein Occlusion (CRVO)","volume":"47","author":"Wells III","year":"2006","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"2025121403524152000_8.12.e022700.76","unstructured":"Wells JA . Safety and efficacy of pegaptanib sodium in treating macular edema secondary to Central Retinal Vein Occlusion. Am Acad Ophthalmol 2006."},{"key":"2025121403524152000_8.12.e022700.77","unstructured":"Ciulla TA . Treatment of macular edema following central retinal vein occlusion with pegaptanib sodium (macugen): a one-year study. Am Acad Ophthalmol 2007."},{"key":"2025121403524152000_8.12.e022700.78","unstructured":"Pegaptanib CKG . Macugen) for Macular edema in Central Retinal Vein Occlusion: early OCT results and effect of therapy reinitiation. American Academy of Ophthamology 2007."},{"key":"2025121403524152000_8.12.e022700.79","first-page":"1544","article-title":"Pegaptanib sodium for the treatment of macular edema following Central Retinal Vein Occlusion (CRVO): functional outcomes","volume":"48","author":"Wells III","year":"2007","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"2025121403524152000_8.12.e022700.80","first-page":"311","article-title":"Pegaptanib sodium for the treatment of macular edema following Central Retinal Vein Occlusion (CRVO): anatomical outcomes","volume":"48","author":"Patel","year":"2007","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"2025121403524152000_8.12.e022700.81","doi-asserted-by":"crossref","first-page":"e530","DOI":"10.1111\/aos.12317","article-title":"Three intravitreal bevacizumab versus two intravitreal triamcinolone injections in recent onset central retinal vein occlusion","volume":"92","author":"Ramezani","year":"2014","journal-title":"Acta Ophthalmol"},{"key":"2025121403524152000_8.12.e022700.82","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ajo.2016.04.020","article-title":"Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label Study","volume":"169","author":"Hoerauf","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"2025121403524152000_8.12.e022700.83","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.07.038"},{"key":"2025121403524152000_8.12.e022700.84","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200326120-00002"},{"key":"2025121403524152000_8.12.e022700.85","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.08-2510"},{"key":"2025121403524152000_8.12.e022700.86","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-011-9249-6"},{"key":"2025121403524152000_8.12.e022700.87","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2415-15-1"},{"key":"2025121403524152000_8.12.e022700.88","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000458534","article-title":"Intravitreal Dexamethasone Implant versus Intravitreal Ranibizumab for the Treatment of Macular Edema Secondary to Retinal Vein Occlusion in a Chinese Population","volume":"58","author":"Gu","year":"2017","journal-title":"Ophthalmic Res"},{"key":"2025121403524152000_8.12.e022700.89","doi-asserted-by":"crossref","unstructured":"Hattenbach LO , Feltgen N , Bertelmann T , et al . Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B). Acta Ophthalmol 2018;96.doi:10.1111\/aos.13381","DOI":"10.1111\/aos.13381"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2018-022700","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T11:52:53Z","timestamp":1765713173000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2018-022700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":89,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2018,12,28]]},"published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1136\/bmjopen-2018-022700"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2018-022700","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]}}}